Can a female patient who cannot tolerate statins or ezetimibe (Zetia) be prescribed evolocumab (Repatha) given a serum sodium of 145 mmol/L and a total cholesterol of 165 mg/dL?

Can She Take Repatha?

Yes, she can take Repatha (evolocumab) as monotherapy given her documented intolerance to both statins and ezetimibe, though the appropriateness depends critically on her cardiovascular risk status and LDL-C level, which you haven't provided. The sodium level of 145 mmol/L is normal and irrelevant to this decision. The total cholesterol of 165 mg/dL alone is insufficient—you need her LDL-C level to make a proper treatment decision.

Key Decision Points

Statin and Ezetimibe Intolerance Context

Multiple guidelines explicitly address this scenario. NICE 2019 guidelines approve PCSK9 inhibitors like evolocumab for high-risk patients who are intolerant to statins or fail to meet LDL-C targets despite statin and ezetimibe therapy 1. The 2022 ACC Expert Consensus acknowledges that some patients "may not tolerate the recommended intensity of statin therapy" and considers nonstatin alternatives 2.

The FDA label confirms evolocumab's efficacy as adjunctive therapy, and the GAUSS-3 trial specifically studied statin-intolerant patients, demonstrating that evolocumab reduced LDL-C by 52.8-54.5% compared to 16.7% with ezetimibe, with muscle symptoms occurring in only 20.7% of evolocumab patients versus 28.8% with ezetimibe 3. Real-world data from Spain showed only 0.5% of patients discontinued evolocumab due to side effects, with 92.3% compliance 4.

The Critical Missing Information: Risk Stratification

You must determine her cardiovascular risk category before prescribing:

• Very high risk (established ASCVD, familial hypercholesterolemia with ASCVD, or >20% 10-year ASCVD risk): Strong indication for PCSK9 inhibitor if LDL-C ≥70 mg/dL 1
• High risk (7.5-20% 10-year risk): Reasonable to consider if LDL-C remains elevated 1
• Intermediate/borderline risk (<7.5% 10-year risk): Generally NOT recommended—the 2022 ACC guidelines explicitly state "the expert consensus writing committee does not recommend routine use of nonstatin therapy for primary prevention patients with ASCVD risk <20%" 2

Practical Algorithm

1. Calculate her LDL-C from the lipid panel (not just total cholesterol)
2. Assess cardiovascular risk:
   • Does she have established ASCVD (prior MI, stroke, PAD)?
   • Does she have familial hypercholesterolemia?
   • Calculate 10-year ASCVD risk if primary prevention
3. Apply treatment thresholds:
   • Very high risk + LDL-C ≥70 mg/dL: Prescribe evolocumab 140 mg every 2 weeks or 420 mg monthly 1
   • High risk + LDL-C ≥100 mg/dL: Consider evolocumab 1
   • Lower risk: Do NOT prescribe—burden outweighs benefit 2, 1

Important Caveats

Monotherapy considerations: While evolocumab is typically used as add-on therapy to statins, clinical practice guidelines and expert opinion support its use as monotherapy in truly statin-intolerant patients 5. The 2022 BMJ guidelines note that evolocumab can be used "in patients who are intolerant to statins" 1.

Document true intolerance: Ensure she has documented intolerance to multiple statins (ideally 2-3 different statins at different doses) and ezetimibe. The GAUSS-3 trial used a rechallenge protocol to confirm true statin intolerance 3.

Cost and access: Evolocumab is expensive. Verify insurance coverage and patient willingness to self-inject 5. Real-world adherence is high (92.3%) when patients are properly selected 4.

Safety profile: Evolocumab does not reduce plasma CoQ10 levels, potentially advantageous for patients with prior statin-associated muscle symptoms 6. Long-term safety data from over 60,000 patient-years show no neurocognitive effects or significant antibody formation 5.

The sodium level is irrelevant—it's normal and has no bearing on lipid-lowering therapy decisions.